Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

CEL-SCI Corporation (NYSE MKT: CVM) announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease. In animal tests this vaccine has shown 1) reduction of number of tumors, 2) reduction of tumor mass, 3) absence of tumor in lymph nodes or peritoneal membranes and 4) changes in angiogenesis. Kenneth S. Rosenthal, Ph.D. of Northeast Ohio Medical University presented these findings in detail at the GTCBIO Immune Responses in the Tumor Microenvironment Workshop, January 30, 2013 to February 1, 2013 in San Diego, CA.

Dr. Rosenthal, Sarah Stone and Robin Edmonds from Northeast Ohio Medical University in collaboration with Dr. Daniel H. Zimmerman, CEL-SCI Corporation's Senior Vice President of Research, Cellular Immunolgy, designed and tested the L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology vaccine. J-HER chemically links the J-ICBL (immune cell binding ligand) peptide to a minimal antigenic peptide (epitope) from the HER-2/neu protein, a protein present in most human breast tumor cells. This protein is the target for different types of immunotherapy with sales of many billions of dollars. Blocking this receptor protein with an antibody causes the tumor cells to commit suicide (apoptosis). The L.E.A.P.S vaccine activates a T lymphocyte response targeted to this protein that promotes killing and control of the tumor cell. In these studies, mice were immunized with the J-HER vaccine before, or one week after implantation of HER-2/neu breast cancer cells. In both cases the immune response initiated by the immunization significantly blocked further development and progression of tumors in most of the animals. Another J-LEAPS vaccine produced similar anti-tumor results in a mouse model for a different cancer by another researcher working with Dr. Rosenthal.

L.E.A.P.S. is a novel peptide platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, including infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic targets for the application of L.E.A.P.S. technology. In addition to the J-HER vaccine, L.E.A.P.S. vaccines have been developed to prevent or treat herpes simplex virus, HIV, influenza and rheumatoid arthritis.

The concept behind the L.E.A.P.S. technology is to mimic cell-cell interactions that activate immune cells with synthetic peptides. Depending upon the type of L.E.A.P.S. construct and ICBL used, CEL-SCI is able to direct the outcome of the immune response. The J-ICBL stimulates the only cell that can initiate an immune response, the dendritic cell. J-LEAPS vaccines activate dendritic cells from humans as well as mice. The activated dendritic cells direct T-cells to deliver the appropriate protective or therapeutic response. For J-HER, this response would activate tumor specific T killer cells. A mixture containing J-HER and similar J-LEAPS vaccines can readily be synthesized and used to treat breast cancers in humans.


CEL-SCI Corporation


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Small molecule can induce self-destruction of pancreatic cancer cells, study finds